Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...

INR:6527. satta satta matka GSK's first BCMA-targeted therapy Blenrep approved in Europe Shengxiang Bio's IPO registration on the Science and Technology Innovat ...

Hol n Win. INR:0679. gbleliciou Hol n Win GSK's first BCMA-targeted therapy Blenrep approved in Europe New standards for administrative penalties for pharmacies are her ...

football rules and regulations GSK's first BCMA-targeted therapy Blenrep approved in Europe Hengrui's two Category 1 new drugs were approved for clinical trials R&D Daily | Regeneron urgently stops ...

satta chart january 2023 GSK's first BCMA-targeted therapy Blenrep approved in Europe Original | Nimbus Military Parade Key clinical results of Sintilimab second-line treatment for locally ...

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...

GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new drug application (NDA) for Blenrep (belantamab mafodotin) in combination ...